Trailing-twelve-month (TTM) revenue is $34.56 Billion. Revenue represents the total income generated from the company's primary business operations.
This company reports half-yearly, so revenue over the trailing two half-years adds its two newest half-year periods instead of four quarters. Amounts are in USD, rounded only to whole currency units.
Reported statement amounts were converted from GBP to USD using the stored FMP exchange-rate calculation.
| Half-year period | Revenue | Source |
|---|---|---|
| Half-year ended 2025-12-31FMP fiscal label: Q4 FY2025 | $18,219,957,140 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-13 |
| Half-year ended 2026-06-30FMP fiscal label: Q2 FY2026 | $16,340,860,118 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-30 |
| Revenue (trailing two half-years) | $34,560,817,258 |
Current P/S: $114,608,360,194 market capitalization ÷ $34,560,817,258 revenue (trailing two half-years) = 3.32x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T19:00:05.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $16.34B.
FMP quote market capitalization / revenue from the trailing two half-years (the two consecutive half-year periods ended 2025-12-31 and 2026-06-30) Quote observation: 2026-10-06T19:00:52.598Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2009-06-30.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · GBP
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2022-12-31 · GBP
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-31 · GBP | FY20202020-12-31 · GBP | FY20212021-12-31 · GBP | FY20222022-12-31 · GBP | FY20252025-12-31 · GBP |
|---|---|---|---|---|---|
| Combustibles | N/A | GBP 22.8B | GBP 22.0B | GBP 23.0B | GBP 20.2B |
| Modern Oral | -GBP 3M | N/A | N/A | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20172017-12-31 · GBP | FY20182018-12-31 · GBP | FY20192019-12-31 · GBP | FY20202020-12-31 · GBP | FY20212021-12-31 · GBP | FY20222022-12-31 · GBP |
|---|---|---|---|---|---|---|
| Foreign countries | N/A | N/A | N/A | N/A | GBP 25.5B | GBP 27.4B |
| Foreign Countries | GBP 20.1B | GBP 24.3B |
$34.56B
$34.56 Billion
N/A
N/A
Compound annual growth rate unavailable
1 Year
N/A
3 Year
N/A
5 Year
N/A
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $34.46B | +$2.10B | +6.48% |
| 2024 | $32.36B | ($2.35B) | (6.77%) |
| 2023 | $34.71B | +$1.29B | +3.86% |
| 2022 | $33.42B | ($1.33B) | (3.84%) |
| 2021 | $34.76B | ($443.60M) | (1.26%) |
| 2020 |
TTM Growth
N/A
3-Year CAGR
N/A
5-Year CAGR
N/A
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 21 comparable quarters.
Current FMP quote-based enterprise value / revenue from the trailing two half-years (the two consecutive half-year periods ended 2025-12-31 and 2026-06-30) Quote observation: 2026-10-06T19:00:52.598Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2009-06-30.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| Others | N/A | GBP 421M | GBP 483M | GBP 522M | GBP 745M |
|---|
| T H P | GBP 35M | N/A | N/A | N/A | N/A |
|---|
| Traditional Oral | N/A | GBP 1.2B | GBP 1.1B | GBP 1.2B | GBP 1.0B |
|---|
| Vapour | GBP 9M | N/A | N/A | N/A | N/A |
|---|
| GBP 25.6B |
| N/A |
| N/A |
| $35.20B |
| +$912.42M |
| +2.66% |
| 2019 | $34.29B | +$3.09B | +9.89% |
| 2018 | $31.20B | +$4.78B | +18.10% |
| 2017 | $26.42B | +$9.00B | +51.64% |
| 2016 | $17.42B | ($1.05B) | (5.67%) |
